IU Liver Research faculty researchers work to help patients overcome barriers that prevent patients from taking part in clinical trials. These barriers may include lack of awareness, fear of side effects, assignment to placebo arm, confusion about insurance coverage and lastly time commitment and travel time to the research facility. Despite these barriers, the research program has had tremendous success over the years with recruitment and retention due to motivated patients who want to have access to new treatments and help advance science.
There have been several breakthroughs in the field of liver disease recently leading to several newer treatment options for liver disorders. These agents are currently under study through various phases of drug development. These phases include Phase 1 (dose finding study), Phase 2 (safety and preliminary efficacy) and Phase 3 (efficacy and safety). Completion of two (rarely one) studies with positive results is often required prior to approval by regulatory authorities.
A complete list of all diabetes clinical trials being conducted at IU School of Medicine can be found on the Indiana Clinical and Translational Sciences Institute (CTSI) website.